- Home
- CHRS vs QBTS Comparison
CHRS vs QBTS Comparison
Compare CHRS & QBTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- QBTS
- Stock Information
- Founded
- CHRS 2010
- QBTS 1999
- Country
- CHRS United States
- QBTS Canada
- Employees
- CHRS N/A
- QBTS N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- QBTS Retail: Computer Software & Peripheral Equipment
- Sector
- CHRS Health Care
- QBTS Technology
- Exchange
- CHRS Nasdaq
- QBTS Nasdaq
- Market Cap
- CHRS 191.3M
- QBTS 1.4B
- IPO Year
- CHRS 2014
- QBTS N/A
- Fundamental
- Price
- CHRS $1.35
- QBTS $7.05
- Analyst Decision
- CHRS Strong Buy
- QBTS Strong Buy
- Analyst Count
- CHRS 4
- QBTS 6
- Target Price
- CHRS $5.38
- QBTS $6.38
- AVG Volume (30 Days)
- CHRS 1.9M
- QBTS 103.1M
- Earning Date
- CHRS 03-12-2025
- QBTS 11-14-2024
- Dividend Yield
- CHRS N/A
- QBTS N/A
- EPS Growth
- CHRS N/A
- QBTS N/A
- EPS
- CHRS N/A
- QBTS N/A
- Revenue
- CHRS $304,340,000.00
- QBTS $9,424,000.00
- Revenue This Year
- CHRS $2.47
- QBTS $4.94
- Revenue Next Year
- CHRS N/A
- QBTS $63.93
- P/E Ratio
- CHRS N/A
- QBTS N/A
- Revenue Growth
- CHRS 44.19
- QBTS 14.27
- 52 Week Low
- CHRS $0.66
- QBTS $0.71
- 52 Week High
- CHRS $2.87
- QBTS $11.41
- Technical
- Relative Strength Index (RSI)
- CHRS 44.90
- QBTS 50.10
- Support Level
- CHRS $1.24
- QBTS $5.91
- Resistance Level
- CHRS $1.45
- QBTS $7.11
- Average True Range (ATR)
- CHRS 0.12
- QBTS 1.10
- MACD
- CHRS -0.03
- QBTS -0.27
- Stochastic Oscillator
- CHRS 19.81
- QBTS 37.35
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About QBTS D-Wave Quantum Inc.
D-Wave Quantum Inc is in the development and delivery of quantum computing systems, software, and services, and it is the commercial supplier of quantum computers and the only company building both annealing quantum computers and gate-model quantum computers. The Company's mission is to unlock the power of quantum computing today to benefit business and society. It delivers customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. Its annealing quantum computers are accessible through the Company's LeapTM cloud service.